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ABSTRACT
Background    At the Division of Functional Genomics, 
Research Center for Bioscience and Technology, Tottori 
University, we have been making an effort to establish a 
genetic testing facility that can provide the same screen-
ing procedures conducted worldwide. 
Methods    Direct sequencing of PCR products is the 
main method to detect point mutations, small deletions 
and insertions. Multiplex ligation-dependent probe am-
plification (MLPA) was used to detect large deletions 
or insertions. Expansion of the repeat was analyzed 
for triplet repeat diseases. Original primers were con-
structed for 41 diseases when the reported primers failed 
to amplify the gene. Prediction of functional effect of 
human nsSNPs (PolyPhen) was used for evaluation of 
novel mutations. 
Results    From January 2000 to September 2013, a total 
of 1,006 DNA samples were subjected to genetic testing 
in the Division of Functional Genomics, Research Cen-
ter for Bioscience and Technology, Tottori University. 
The hospitals that requested genetic testing were located 
in 43 prefectures in Japan and in 11 foreign countries. 
The genetic testing covered 62 diseases, and mutations 
were detected in 287 out of 1,006 with an average muta-
tion detection rate of 28.5%. There were 77 samples for 
prenatal diagnosis. The number of samples has rapidly 
increased since 2010. 
Conclusion    In 2013, the next-generation sequencers 
were introduced in our facility and are expected to pro-
vide more comprehensive genetic testing in the near fu-
ture. Nowadays, genetic testing is a popular and powerful 
tool for diagnosis of many genetic diseases. Our genetic 
testing should be further expanded in the future.  
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line mutation 
 
The development of new technologies such as microar-
ray analysis and next-generation sequencing has enabled 
more comprehensive screening for mutations that cause 
inherited diseases.1, 2 According to GeneTests (http://
www.genetests.org/), screening methods covering more 
than 2,000 genes are currently available.
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 In Japan, however, genetic testing has not yet be-
come a common practice in the medical field, since 
public insurance covers only screenings for mutations 
in 36 genes. Mutation hunting on several genes is con-
ducted on a research basis, which as expected depends 
on the research project and is not ensured to be provided 
in the future.
 In the Division of Functional Genomics, Research 
Center for Bioscience and Technology, Tottori Univer-
sity, we have established a genetic testing facility that 
can provide the same screening procedures conducted 
worldwide. This system started as a service for screening 
mutations responsible for several types of inherited dis-
orders of children, and now has expanded to cover more 
than 60 inherited disorders. Human DNA samples have 
been provided not only from Tottori University Hospital 
but also from other medical facilities all over Japan and 
foreign countries. Here the development of the system 
from January 2000 to September 2013 is reported.
 
SUBJECTS AND METHODS
Subjects
From January 2000 to September 2013, a total of 1,006 
DNA samples were subjected to genetic testing in our 
facility. They were from 13 departments at Tottori Uni-
versity Hospital, 123 hospitals in Japan and 11 in foreign 
countries (Table 1). Most of the DNA was extracted 
from peripheral blood. Exceptions include 24 from cul-
tured fibroblasts and 3 from tissue. For prenatal diagno-
sis, 40 DNA samples were from chorionic villi, 36 from 
cultured amnionic cells and 1 from umbilical blood. The 
DNA was subjected to genetic testing for 62 inherited 
diseases (Table 2).
 The samples were collected according to “Guide-
line for Genetic Testing” (August 2005) approved by 
the Association of Genetic Medicine (10 societies and 
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Table 1. The number of medical facilities that requested for genetic testing in our laboratory* 
Area  Number Perfecture or Country
Hokkaido 5
Tohoku 10 Aomori 1, Iwate 1, Miyagi 3, Akita 1, Yamagata 2, Fukushima 2
Kanto 27 Ibaragi 1, Tochigi 3, Gunma 2, Saitama 4, Chiba 2, Tokyo 11, Kanagawa 4
Chubu 20 Niigata 2, Ishikawa 2, Fukui 1, Yamanashi 1, Nagano 1, Gifu 1, Shizuoka 4, Aichi 8
Kinki 20 Mie 3, Shiga 3, Kyoto 2, Osaka 8, Hyogo 3, Nara 1
Chugoku 19 Tottori 4, Shimane 1, Okayama 5, Hiroshima 6, Yamaguchi 3
Shikoku 3 Tokushima 1, Kagawa 2 
Kyusyu 19 Fukuoka 5, Saga 1, Nagasaki 2, Kumamoto 1, Oita 4, Miyazaki 1, Kagoshima 3, Okinawa 2
   Total 123 
Foreign countries 11 United Kingdom 1, Macedonia 1, United Arab Emirates 1, United States 1, India 1, Singapore 1, Turkey 1, 
Thailand 1, China 1, Belgium 1, Russia 1
*Tottori University Hospital excluded. 
1 committee), and also according to the “Guidelines 
for Genetic Tests and Diagnoses in Medical Practice” 
(February 2011) approved by the Japanese Association 
of Medical Sciences. Prenatal diagnosis was approved 
by the Ethical Committee of Tottori University.
 
Methods
Direct Sequencing of the PCR product is the main 
method to detect point mutations, small deletions and 
insertions. In the past, single strand conformation poly-
morphism (SSCP) and denaturing high performance 
liquid chromatography (DHPLC) were used in mutation 
screenings for porphyria, holoprosencephaly and Joubert 
Syndrome. Mutations in the aberrant PCR product de-
tected by SSCP or DHPLC were confirmed by direct 
sequencing. SSCP and DHPLC were used from Janu-
ary 2000 to October 2001, and from July 2004 to April 
2010, respectively.
 The length of the triplet repeat was determined in 
the diagnosis of myotonic dystrophy, fragile X syndrome 
and dentatorubral-pallidoluysian atrophy. Multiplex 
ligation-dependent probe amplification (MLPA) was 
used for diagnosis of Fabry disease, Rett syndrome, 
Pelizaeus-Merzbacher disease, Duchenne muscular dys-
trophy,  von Hippel-Lindau disease and spinal muscular 
atrophy, because these diseases are often caused by large 
deletions and insertions. Real-time PCR was specially 
used to detect deletions or insertions in the genes that 
cause Pelizaeus-Merzbacher disease, Gaucher disease, 
Menkes disease and metachromatic leukodystorophy.
 
Disease and gene information 
Information on diseases and causative genes was ob-
tained from Online Mendelian Inheritance in Man and 
Gene database provided by the National Center for Bio-
technology Information.
PCR
Before 2009, the primers were designed according to pub-
lished data with variable rates of successful amplification. 
From 2010, almost all primers were designed originally in 
our laboratory using Primer3 software utilizing the gene 
information from Entrez Gene and RefSeq, resulting in 
successful amplification in almost all cases. The coding 
sequence with 70 bp of the flanking area of each exon was 
amplified by PCR. The annealing temperature was set 
relatively high (around 63 ˚C) (Table 2). The sequences of 
the primers are available on request.
 AmpliTaq Gold (Life Technologies, Carlsbad, CA) 
was routinely used except for the amplification of GC 
rich sequences (more than 70%). For GC rich sequences, 
TaKaRa LA Taq (Takara Bio, Otsu, Japan) was used. 
The reaction mixture contained in a 10 µL reaction vol-
ume 10 to 100 ng of template DNA, 2.5 U AmpliTaq 
Gold, 250 µM or 400 µM dNTP, 1 µM of each primer 
(forward and reverse) and was run at the following con-
ditions: initial denaturation at 95 ˚C for 5 min, followed 
by 30 cycles with denaturaion at 95 ˚C for 1 min, anneal-
ing at 60 ˚C for 1 min, extension at 72 ˚C for 1 min and 
final extension at 72 ˚C for 5 min. For GC-rich or rela-
tively long sequences, 0.5 U TaKaRa LA Taq was used 
instead of AmpliTaq Gold. The reaction contained 400 
µM dNTP and was run as follows: initial denaturation at 
94 ˚C for 1 min, followed by 30 cycles with denaturaion 
at 94 ˚C for 30 s, annealing at 60 ˚C for 30 s, extension 
at 72 ˚C for 2 min and final extension at 72 ˚C for 5 min.
 For diagnosis of incontinentia pigmenti and 
Fukuyama-type congenital muscular dystrophy, long 
insertion or deletion was detected according to the meth-
ods described by Bardaro et al.3 and Kato et al.4, respec-
tively.
 
Direct sequencing 
PCR products were run on 1.5% of agarose gel electro-
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Table 2. List of inherited diseases surveyed for genetic mutations in our facility
Disease Gene symbol Number of genetic cases 
Myotonic dystrophy DM1 250* 115‡
Fragile X syndrome FMR1 173 19‡
Niemann-Pick disease type C NPC1† 73* 24‡
GM1 gangliosidosis GLB1 56* 20‡
Joubert syndrome NPHP1†, CEP290†, AHI1†, TMEM67, RPGRIP1L 42* 9‡
Gaucher disease GBA 40* 9‡
Tay-Sachs disease HEXA 38* 12‡
Porphyria HMBS†, PPOX†, CPOX† 38 3‡
Pompe disease GAA 32 8‡
Cowden syndrome PTEN 30 6‡
Fabry disease GLA 28 5‡
Menkes disease ATP7A† 23* 3‡
Metachromatic leukodystrophy ARSA† 19* 4‡
Rett syndrome/MECP2-related disorders MECP2 13 4‡
X-linked hydrocephalus L1CAM 13* 3‡
Pelizaeus-Merzbacher disease PLP1 11* 3‡
Fukuyama-type congenital muscular dystrophy FKTN 10* 4‡
Nephrogenic diabetes insipidus (NDI) AVPR2 10 3‡
Myotubular myopathy MTM1† 9 1‡
Galactosialidosis CTSA 8 4‡
Duchenne muscular dystrophy DMD 7* 3‡
Von Hippel-Lindau disease VHL† 5 3‡
Spinal muscular atrophy SMN1 5* 0‡
Dentatorubral-pallidoluysian atrophy (DRPLA) ATN1 4 2‡
Tuberous sclerosis TSC1†, TSC2† 4 2‡
Limb-girdle muscular dystrophy type 2B (LGMD2B) DYSF† 4 1‡
Pendred syndrome SLC26A4† 3 3‡
Enlarged parietal foramina ALX4†, MSX2† 3 2‡
Sialidosis NEU1 3 2‡
Congenital muscular dystrophy-dystroglycanopathy FKRP† 3 0‡
Methylmalonic acidemia MMAA†, MMAB†, MMADHC†, MUT† 3 0‡
Niemann-Pick disease type C2 NPC2† 3 0‡
Benign hereditary chorea NKX2-1 2 2‡
Li-Fraumeni syndrome TP53 2 2‡
Mucopolysaccharidosis type IVB (Morquio) GLB1 2 2‡
Dyschromatosis symmetrica hereditaria ADAR† 2 1‡
Incontinentia pigmenti IKBKG 2 1‡
Melanoma CDKN2A† 2 1‡
Calcium-sensing receptor CASR 2 0‡
Dopamine transporter SLC6A3 2 0‡
Familial dysautonomia IKBKAP 2 0‡
Holoprosencephaly SHH, ZIC2† 2 0‡
Lesch-Nyhan syndrome HPRT1 2* 0‡
Mitochondrial diseases – 2 0‡
Papillon-Lefevre disease CTSC† 2 0‡
Werner Syndrome WRN† 1 1‡
Ceroid lipofuscinosis, neuronal, 1  PPT1† 1 0‡
Feingold syndrome MYCN† 1 0‡
Gardner syndrome AXIN1† 1 0‡
GM2-gangliosidosis, AB variant GM2A† 1 0‡
Greig cephalopolydactyly syndrome GLI3† 1 0‡
Growth hormone receptor GHR 1 0‡
Klippel-Feil syndrome GDF6† 1 0‡
Leber hereditary optic neuropathy – 1 0‡
Limb-girdle muscular dystrophy type 1C (LGMD1C) CAV3 1 0‡
Nevoid Basal Cell Carcinoma syndrome PTCH1† 1 0‡
Niemann-Pick disease type B SMPD1† 1 0‡
Ornithine carbamoyltransferase deficiency disease OTC† 1 0‡
Pseudohypoparathyroidism  GNAS† 1 0‡
Sialic acid storage disease SLC17A5† 1 0‡
Townes-Brocks syndrome SALL1 1 0‡
Zellweger syndrome PEX26† 1 0‡
Total  1006 287‡ 
*The number includes the cases of prenatal diagnosis
†The PCR primers were originally designed in our laboratory
‡The number indicates the cases of mutation.
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Table 3. The number of cases subjected to genetic 
testing from January 2000 to September 2013
 Number of cases Number
  Tottori University Other  of
Year Total Hospital hospitals diseases
 2000 6 6  0 2
2001 6 6 0 4
2002 2 2 0 1
2003 7 7 0 3
2004 18 18 0 7
2005 21 21 0 8
2006 44 25 19 13
2007 43 9 34 5
2008 87 18 69 17
2009 74 18 56 20
2010 128 55 73 24
2011 219 78 141 29
2012 198 70 128 26
2013* 153 54 99 27
Total 1006 387 619
 * January to September 2013.
phoresis and were purified by Ultrafree-DA centrifugal 
filter unit (Millipore, Billerica, MA). The sequence was 
determined by using BigDye Terminator v3.1 Cycle Se-
quencing Kit and capillary sequencer 3130xL Genetic 
Analyzer (Life Technologies).
SSCP
As described previously, PCR products were separated 
on 12% polyacrylamide gel at room temperature or 4 ˚C, 
and were visualized by silver staining.5
 
DHPLC 
A WAVE-MD Mutation Detection System (Transgenomic, 
Omaha, NE) based on the DHPLC method was used 
to detect heteroduplex states according to the manufac-
turer’s instructions.
Fragment analysis for triplet repeat diseases 
PCR in a total volume of 10 µL contained 100 ng of 
DNA, 2.5 U AmpliTaq Gold DNA Polymerase, 250 µM 
dNTP, 10% DMSO, 1 µM each primer (forward and 
reverse), 0.1 µM of the fluorescent labeled probe (FAM, 
HEX or NED) and was run as follows: initial denatur-
ation at 94 ˚C for 5 min, followed by 30 cycles with 
denaturation at 95 ˚C for 1 min, annealing at 55 ˚C for 
1 min, extension at 72 ˚C for 1 min, and final extension 
at 72 ˚C for 5 min. The PCR products were mixed with 
GeneScan 500 ROX Size Standard (Life Technologies). 
After incubation at 95 ˚C for 5 min, the samples were 
immediately cooled and electrophoresed by 3130xL Ge-
netic Analyzer. Before 2005, ALFred DNA Sequencer 
(Amersham Pharmacia Biotech, Piscataway, NJ) was 
used.
MLPA
An MLPA kit (MRC-Holland, Amsterdam, the Nether-
lands) was used according to the manufacturer’s instruc-
tions. In brief, 80 mg of DNA in 6% of glycerol was in-
cubated at 98 ˚C for 15 min for initial denaturation. The 
final reaction mixture was electrophoresed by a 3130xL 
Genetic Analyzer using a 50 cm-long capillary POP-7.
 
Real-time PCR 
When there was any inconsistency in the results of mu-
tations in family members, real-time PCR was used to 
confirm the presence of deletions or duplications around 
the mutations.
Data analysis 
Sequence data was analyzed by Sequence Scanner (Life 
Technologies) and Genetyx Software (Genetyx, Shibuya, 
Japan). Variant Reporter Software (Life Technologies) 
was used for detection of mutations from 2011. The mu-
tations were confirmed using the human genome muta-
tion database (BIOBASE, Halchtersche, Germany) and 
SNP database. Prediction of functional effect of human 
nsSNPs (PolyPhen) was used for evaluation of novel mu-
tations.6
 Fragment analysis data was analyzed by Peak Scan-
ner Software v1.0 (Life Technologies) for the repeat 
size. MLPA data was analyzed by Coffalyzer Software 
(MRC-Holland).
The personale and running processes of the facility
After October 2010, the working force to run the facility 
consists of 1 senior medical genetist, 1 assistant profes-
Fig. 1. The number of DNA samples subjected to genetic testing 
from January 2000 to September 2013. Vertical bars show the 
number of cases. Light gray shows the number from other hospi-
tals, dark gray shows the number from Tottori University Hospital. 
Dots show the number of diseases.
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Fig. 2. A flow chart of the genetic diagnosis using direct sequencing of PCR products. When the system has not been established, it is 
necessary to obtain the genetic information and design new PCR primers. In this case, it takes at least 3 weeks to detect mutations. When 
the system has already been established, it takes 2 weeks.
sor and 6 part-time staff. The diagnostic procedures are 
separated into steps such as DNA preparation, PCR, 
purification, etc., each of which takes approximately 3 
working hours, and the samples were processed sequen-
tially by the part-time staff. The senior medical genetist 
is responsible for genetic counseling to the patients and 
family members, as well as conformation of mutations 
and preparation of the final report.
 
RESULTS
Distribution of the hospitals that requested for ge-
netic testing 
The hospitals that requested for genetic testing were lo-
cated 43 in prefectures of Japan and in 11 foreign coun-
tries (Table 1).
 
The number of DNA samples subjected to genetic 
testing 
A total of 1,006 genetic tests covering 62 diseases were 
performed from January 2000 to September 2013 (Table 
2). The numbers of samples exceeded 50 in myotonic 
dystrophy, fragile X syndrome, Niemann-Pick disease 
type C and GM1-gangliosidois. Original primers were 
constructed for 41 diseases. The number of genetic tests 
gradually increased year by year and did so rapidly af-
ter we introduced a new service system in 2010 (Table 
3, Fig. 1). All samples were analyzed individually, and 
mutations were detected in 287 out of 1,006 with an 
average mutation detection rate of 28.5%. Prenatal di-
agnosis covered 13 diseases and 77 DNA samples were 
analyzed.
 
Flow chart of genetic testing 
After 2010, it started to take at least 2 weeks for each ge-
netic test to be completed. An additional one and a half 
weeks is required if it is necessary to settle new screen-
ing procedures (Fig. 2). PolyPhen software was used 
to predict whether any mutation detected was disease-
causing or not.
 
DISCUSSION
We have received a number of requests for genetic test-
ing from all over Japan. Institutes that provide genetic 
testing are rare, and our institute provides a unique func-
tion for the Japanese scientific and medical fields. Actu-
ally, genetic testing has contributed to several scientific 
reports.7–18 The number of cases of myotonic dystrophy 
was particularly high partly because the genetic testing 
was approved by Ministry of Health, Labour and Wel-
fare of Japan as “highly advanced medical treatment”. 
It may also be because our facility is the only one ap-
proved for conducting prenatal diagnosis of this disease 
in Japan.19 The numbers of cases of fragile X syndrome, 
Niemann-Pick disease type C, GM1-gangliosidosis and 
other lysosomal storage diseases are also high because 
these diseases were the subjects of active research at 
Tottori University.20–22
 Direct sequencing by a capillary sequencer is the 
main method of genetic testing and the size of the repeat 
was analyzed for triplet repeat diseases. MLPA was 
used for deletions or insertions of exons. For Joubert 
syndrome, 19 or more disease-causing genes were re-
ported. Direct sequencing of every exon of all genes is 
impractical. In such cases, SSCP or DHPLC was used 
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for initial screening. These methods are prone to give 
false-negative results and it will be better to use next-
generation sequencers,23–25 which were introduced to 
Tottori University in 2013.
 The efficiency of genetic testing has improved and 
new lines of genetic testing have been enabled since 
2010 by the improvement of running processes. Genetic 
testing is often still conducted based on research, and the 
expense is usually paid for by research funds. Because 
the expense is limited and genetic testing is necessary 
for clinical diagnosis of many inherited diseases, the 
costs should be included in medical expenses. At Tottori 
University Hospital, we have settled on basic original 
rules that enable us to refer the cost to the patient or cli-
ent.
 Genetic testing performed for research lacks the 
high quality required in clinics. In the United States 
and Europe, the quality of genetic testing is secured by 
Clinical Laboratory Improvement Amendments.26 Un-
fortunately there is no guideline for quality control in 
Japan. At our facility, testing is performed according to 
the Standard Operating Procedures and the information 
is shared by each member. Genetic testing is now a pop-
ular and powerful tool for diagnosis of many inherited 
diseases. We should promote it further in the future.
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